- Home
- MNKD vs NVAX Comparison
MNKD vs NVAX Comparison
Compare MNKD & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- NVAX
- Stock Information
- Founded
- MNKD 1991
- NVAX 1987
- Country
- MNKD United States
- NVAX United States
- Employees
- MNKD N/A
- NVAX N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MNKD Health Care
- NVAX Health Care
- Exchange
- MNKD Nasdaq
- NVAX Nasdaq
- Market Cap
- MNKD 1.7B
- NVAX 1.4B
- IPO Year
- MNKD 2004
- NVAX 1995
- Fundamental
- Price
- MNKD $5.33
- NVAX $8.64
- Analyst Decision
- MNKD Strong Buy
- NVAX Hold
- Analyst Count
- MNKD 5
- NVAX 6
- Target Price
- MNKD $10.80
- NVAX $11.33
- AVG Volume (30 Days)
- MNKD 4.4M
- NVAX 4.7M
- Earning Date
- MNKD 11-05-2025
- NVAX 11-11-2025
- Dividend Yield
- MNKD N/A
- NVAX N/A
- EPS Growth
- MNKD 149.32
- NVAX N/A
- EPS
- MNKD 0.11
- NVAX 2.54
- Revenue
- MNKD $301,736,000.00
- NVAX $1,078,718,000.00
- Revenue This Year
- MNKD $14.78
- NVAX $61.25
- Revenue Next Year
- MNKD $19.36
- NVAX N/A
- P/E Ratio
- MNKD $50.09
- NVAX $3.42
- Revenue Growth
- MNKD 21.48
- NVAX 9.22
- 52 Week Low
- MNKD $3.38
- NVAX $5.01
- 52 Week High
- MNKD $7.63
- NVAX $11.55
- Technical
- Relative Strength Index (RSI)
- MNKD 49.48
- NVAX 50.79
- Support Level
- MNKD $5.28
- NVAX $8.19
- Resistance Level
- MNKD $5.62
- NVAX $8.75
- Average True Range (ATR)
- MNKD 0.24
- NVAX 0.38
- MACD
- MNKD -0.02
- NVAX -0.04
- Stochastic Oscillator
- MNKD 58.80
- NVAX 46.97
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.